249 related articles for article (PubMed ID: 29987746)
1. Application of tumor treating fields for newly diagnosed glioblastoma: understanding of nationwide practice patterns.
McClelland S; Sosanya O; Mitin T; Degnin C; Chen Y; Attia A; Suh JH; Jaboin JJ
J Neurooncol; 2018 Oct; 140(1):155-158. PubMed ID: 29987746
[TBL] [Abstract][Full Text] [Related]
2. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
3. Tumor Treating Fields Utilization in a Glioblastoma Patient with a Preexisting Cardiac Pacemaker: The First Reported Case.
McClelland S; Henrikson CA; Ciporen JN; Jaboin JJ; Mitin T
World Neurosurg; 2018 Nov; 119():58-60. PubMed ID: 30064027
[TBL] [Abstract][Full Text] [Related]
4. Neuro-oncology practices in Australia: a Cooperative Group for Neuro-Oncology patterns of care study.
Chen JY; Hovey E; Rosenthal M; Livingstone A; Simes J
Asia Pac J Clin Oncol; 2014 Jun; 10(2):162-7. PubMed ID: 23714694
[TBL] [Abstract][Full Text] [Related]
5. First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.
O'Connell D; Shen V; Loudon W; Bota DA
CNS Oncol; 2017 Jan; 6(1):11-18. PubMed ID: 27918194
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of tumor treating fields therapy for high-grade gliomas.
Shah PP; White T; Khalafallah AM; Romo CG; Price C; Mukherjee D
J Neurooncol; 2020 Jul; 148(3):433-443. PubMed ID: 32578135
[TBL] [Abstract][Full Text] [Related]
7. Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies.
Mittal S; Klinger NV; Michelhaugh SK; Barger GR; Pannullo SC; Juhász C
J Neurosurg; 2018 Feb; 128(2):414-421. PubMed ID: 28298023
[TBL] [Abstract][Full Text] [Related]
8. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.
Mehta M; Wen P; Nishikawa R; Reardon D; Peters K
Crit Rev Oncol Hematol; 2017 Mar; 111():60-65. PubMed ID: 28259296
[TBL] [Abstract][Full Text] [Related]
9. Current usage of tumor treating fields for glioblastoma.
Lassman AB; Joanta-Gomez AE; Pan PC; Wick W
Neurooncol Adv; 2020; 2(1):vdaa069. PubMed ID: 32666048
[TBL] [Abstract][Full Text] [Related]
10. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.
Trusheim J; Dunbar E; Battiste J; Iwamoto F; Mohile N; Damek D; Bota DA; Connelly J
CNS Oncol; 2017 Jan; 6(1):29-43. PubMed ID: 27628854
[TBL] [Abstract][Full Text] [Related]
11. Tumor Treating Fields in Neuro-Oncological Practice.
Mrugala MM; Ruzevick J; Zlomanczuk P; Lukas RV
Curr Oncol Rep; 2017 Aug; 19(8):53. PubMed ID: 28664468
[TBL] [Abstract][Full Text] [Related]
12. Tumour Treating Fields (TTFs) for recurrent and newly diagnosed glioblastoma multiforme.
Mirza FA; Shamim MS
J Pak Med Assoc; 2018 Oct; 68(10):1543-1545. PubMed ID: 30317361
[TBL] [Abstract][Full Text] [Related]
13. Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma.
Majd P; O'Connell DE; Kim RC; Bota DA; Carrillo JA
CNS Oncol; 2017 Apr; 6(2):89-94. PubMed ID: 28303729
[TBL] [Abstract][Full Text] [Related]
14. Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation.
Kim EH; Kim YH; Song HS; Jeong YK; Lee JY; Sung J; Yoo SH; Yoon M
Oncotarget; 2016 Sep; 7(38):62267-62279. PubMed ID: 27556699
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review.
Fabian D; Guillermo Prieto Eibl MDP; Alnahhas I; Sebastian N; Giglio P; Puduvalli V; Gonzalez J; Palmer JD
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30717372
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.
Bernard-Arnoux F; Lamure M; Ducray F; Aulagner G; Honnorat J; Armoiry X
Neuro Oncol; 2016 Aug; 18(8):1129-36. PubMed ID: 27177573
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy.
Saria MG; Kesari S
Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S9-S13. PubMed ID: 27668388
[TBL] [Abstract][Full Text] [Related]
19. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
Stupp R; Wong ET; Kanner AA; Steinberg D; Engelhard H; Heidecke V; Kirson ED; Taillibert S; Liebermann F; Dbalý V; Ram Z; Villano JL; Rainov N; Weinberg U; Schiff D; Kunschner L; Raizer J; Honnorat J; Sloan A; Malkin M; Landolfi JC; Payer F; Mehdorn M; Weil RJ; Pannullo SC; Westphal M; Smrcka M; Chin L; Kostron H; Hofer S; Bruce J; Cosgrove R; Paleologous N; Palti Y; Gutin PH
Eur J Cancer; 2012 Sep; 48(14):2192-202. PubMed ID: 22608262
[TBL] [Abstract][Full Text] [Related]
20. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
